Wells Fargo analyst Mohit Bansal raised the firm’s price target on Halozyme (HALO) to $60 from $57 and keeps an Equal Weight rating on the shares. The firm notes the company’s Q4 was good, with royalty revenues at $170M vs. $158M consensus. While the company did not update 2025 guidance, Wells thinks there could be upside since Vyvgart launch in CIDP appears to be going well.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Therapeutics: Record Earnings and Future Growth
- Halozyme price target raised to $78 from $73 at Citizens JMP
- Buy Rating Affirmed: Halozyme’s Robust Growth and Strategic Positioning Drive Positive Outlook
- Halozyme price target raised to $72 from $70 at H.C. Wainwright
- Halozyme Therapeutics Achieves Record Revenue in 2024